Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient (Q36152460)

12 August 2017

0 references

Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient (English)

1 reference

12 August 2017

1 reference

Małgorzata Mackiewicz-Wysocka

1

1 reference

12 August 2017

Lukasz Krokowicz

2

1 reference

12 August 2017

Jacek Kocur

3

1 reference

12 August 2017

Jacek Mackiewicz

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 2014

1 reference

12 August 2017

1 reference

12 August 2017

93

1 reference

12 August 2017

27

1 reference

12 August 2017

e157

1 reference

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Resistance to BRAF-targeted therapy in melanoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Mutant BRAF melanomas--dependence and resistance

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4602769

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25501056

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/MD.0000000000000157

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

25501056

1 reference